Dr. Max Søgaard joined ExpreS2ion in 2013 and has been instrumental in advancing ExpreS2ion's proprietary S2 technology ExpreS2, helping it reach its current status as a novel Phase III-proven platform. Most recently serving as Senior Vice President R&D and Technology, his leadership has been critical in the shaping the company's R&D strategy and pipeline.

Dr. Max Søgaard commented on his promotion: "With our lead therapeutic breast cancer vaccine asset ES2B-C001 progressing in clinical Phase I, a robust pipeline of promising candidates addressing unmet needs in infectious diseases, and an innovative protein production platform, I am excited to take on the role as CSO. I look forward to continuing our mission to develop next-generation vaccines that can make a meaningful impact on global health."

Bent Frandsen, Chief Executive Officer added: "Max's deep scientific expertise and leadership make him the ideal choice to drive ExpreS2ion's research and development efforts forward. I am confident that under his guidance, we will continue to innovate and advance our pipeline toward successful value trigger points."

Bent Frandsen concluded: "I want to sincerely thank Farshad for his invaluable contributions over the past two years as CSO. His four decades of expertise in vaccine research and development have been instrumental in ExpreS2ion's progress, and I am pleased that he will continue to provide strategic guidance in his new advisory role."